Homburger advised the joint book-running managers in connection with the public offering of an aggregate 4,887,500 common shares in CRISPR Therapeutics AG
On November 20, 2019, CRISPR Therapeutics AG, a leading gene editing company based in Zug, Switzerland, focusing on developing transformative gene-based medicines for serious diseases based on its proprietary CRISPR/Cas9 technology, and each of Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC, as joint book-running managers, and each of Chardan Capital Markets, LLC, Oppenheimer & Co. Inc., BTIG, LLC and Roth Capital Partners, LLC, as co-managers, entered into an underwriting agreement relating to the public offering of 4,250,000 common shares at a price of USD 64.50 per share, before underwriting discounts. On November 26, 2019, the underwriters exercised in full an over-allotment option granted to them under the underwriting agreement to purchase an additional 637,500 common shares in CRISPR Therapeutics AG at the offer price. Comprising an aggregate 4,887,500 common shares in CRISPR Therapeutics AG, the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, are approximately USD 315.2 m. The base offering closed on November 25, 2019 and the over-allotment option closed on December 2, 2019.
Homburger AG acted as legal counsel to Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC as the joint book-running managers and representatives of the several underwriters in the offering. The Homburger team comprised partner Frank Gerhard and associate Lorenzo Togni (both Corporate / M&A and Capital Markets).